AOTI LIMITED

Aoti Limited is a medical-technology company dedicated to improving wound-care outcomes through its proprietary Topical Wound Oxygen (TWO2) system. By combining high-pressure oxygen delivery, non-contact cyclical compression and fine-mist humidification, TWO2 creates a multi-modality environment that restores normal wound metabolism, reduces oedema and promotes neovascularisation, enabling more durable healing of acute and chronic wounds - particularly diabetic foot ulcers.

Backed by real-world evidence studies and a randomised controlled trial, Aoti's solution has demonstrated long-term reductions in wound recurrence, hospitalisations and amputations, translating into lower overall costs of care. The American Diabetes Association has awarded the therapy an A-grade adjunctive treatment recommendation, and leading podiatric and vascular surgeons endorse it as a "mainstay" of modern practice. Aoti supports clinicians with product demonstrations and collaborates with partners to broaden access, while patients benefit from a home-based therapy that delivers hospital-level care in a convenient, cost-effective format.